News
Apr 16, 2026
Long-term use of approved therapy safely extends patient survival, data showStarting Attruby (acoramidis) early and taking it continuously helps adults with…
Apr 16, 2026
A new study demonstrated that naturally occurring antibodies targeting transthyretin (TTR) are present in the serum of both healthy individuals and patients with…
Apr 15, 2026
The modified-comprehensive Kumamoto Score (mKS) can be used as a validated comprehensive tool for the assessment of hereditary transthyretin amyloidosis (ATTR),…
Apr 15, 2026
Samples can be collected from anywhere in India and sent to the National Reference Lab, Rohini, New Delhi, for testingDr Lal PathLabs has introduced Amyloid Typing…
Apr 15, 2026
Introduction: Cardiac amyloidosis is an infiltrative cardiomyopathy with high morbidity and mortality, frequently presenting as heart failure (HF) with preserved…
Apr 15, 2026
Transthyretin amyloidosis is driving intensive pharmaceutical IP activity across four mechanistically distinct modalities — RNAi silencing, small-molecule…
Apr 15, 2026
Transthyretin (ATTR) amyloidosis is a progressive systemic disease associated with substantial morbidity and mortality. Although health-related quality of life (…
Apr 14, 2026
The Amyloidosis Research Consortium’s Executive Director of Research, Kristen Hsu, discussed the current clinical trial landscape in AL amyloidosis. She reviewed…
Apr 14, 2026
Hereditary transthyretin amyloidosis (ATTRv) is a genetic disorder caused by more than 100 autosomal dominant mutations in the TTR gene. Owing to its marked…
Apr 13, 2026
Broad screening criteria of high-risk patients referred for technetium-99m-pyrophosphate (99mTc-PYP) scintigraphy led to a diagnosis of transthyretin-mediated…